Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.
By J. Neoptolemos, J. Dunn, D. Stocken, J. Almond, K. Link, H. Beger, C. Bassi, M. Falconi, P. Pederzoli, C. Dervenis and 7 more. The Lancet, 2001
1,043 citations recorded by the source corpus.
Subfields: Epidemiology, Oncology, Surgery
View Paper: https://www.semanticscholar.org/paper/cca2f36ad2010b9224b35a2ef51336a4a4659861
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
Citations in the corpus
- A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. (2004, neutral): “(%) No Yes Unknown 101 (70) 29 (20) 15 (10) 102 (71) 30 (21) 12 (8) 106 (72) 24 (16) 17 (12) 97 (68) 35 (25) 10 (7) 203 (70) 59 (20) 27 (9)”
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, methodology): “In the ESPAC-1 multicentre randomised trial, a 2 × 2 factorial design, 289 patients treated with curative resection and complete gross resection received one of four therapeutic modalities: exclusive adjuvant chemotherapy [bolus 5-fluorouracil (5-FU) and folinic acid], chemoradiation only (split cou”